

**Filed On Behalf Of:**

Sanofi Mature IP

**By:**

Daniel J. Minion  
dminion@venable.com  
212-218-2100

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

NEPTUNE GENERICS, LLC  
Petitioner,  
v.  
AVENTIS PHARMA S.A.  
Patent Owner.

---

Case IPR2019-00136  
U.S. Patent No. 5,847,170

---

**PATENT OWNER'S EXHIBIT LIST**

## PATENT OWNER'S EXHIBIT LIST

Pursuant to 37 C.F.R. § 42.63(e), Patent Owner respectfully submits the following current exhibit list.

Exhibit	Description
2001	de Bono <i>et al.</i> , “Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial,” 376:1147-54, <i>Lancet</i> , 2010 (“deBono”)
2002	Sanofi Press Release, Phase III Data Showing Improved Survival with Jevtana® (cabazitaxel) Injection in Second-Line Advanced Prostate Cancer Published in The Lancet – Results of the Phase III TROPIC Global Study Published, (Oct. 9, 2010, last accessed Jan. 23, 2019 at <a href="http://www.news.sanofi.us/press-releases?item=118536&amp;printable">http://www.news.sanofi.us/press-releases?item=118536&amp;printable</a> )
2003	United States Patent No. 5,229,526 (“526 patent”)
2004	United States Patent No. 5,319,112 (“112 patent”)
2005	International Patent Application Publication No. WO 94/18164
2006	Ojima <i>et al.</i> , “Synthesis and biological activity of 3’-alkyl- and 3’-alkenyl-3’-dephenyldocetaxels,” 4(21): 2631-34, <i>Bioorg. &amp; Medicinal Chem. Lett.</i> , 1994 (“Ojima”)

Exhibit	Description
2007	Graham L. Patrick, Ch. 7, “ <i>Drug Development</i> ,” in <i>An Introduction to Medicinal Chemistry</i> , (Oxford University Press, eds., 1995)
2008	Dolatrai M. Vyas, Ph.D. & John F. Kadow, Ph.D., Ch. 6 “ <i>Paclitaxel: A Unique Tubulin Interacting Anticancer Agent</i> ,” in <i>Progress in Medicinal Chemistry</i> 32, (Ellis & Luscombe, eds.) (“Vyas”)
2009	Vrignaud <i>et al.</i> , “Preclinical Antitumor Activity of Cabazitaxel, a Semisynthetic Taxane Active in Taxane-Resistant Tumors,” 19(11):2973-83, <i>Clin. Cancer Res.</i> , 2013 (“Vrignaud 2013”)
2010	Defendants’ Post-Trial Brief, filed in <i>Sanofi-Aventis U.S. LLC et al. v. Fresenius Kabi USA, LLC</i> , 3:14-cv-017869-MAS-LHG, D.I. 272-1 (D.N.J. Nov. 1, 2017)
2011	<i>Mylan Labs. Ltd. v. Aventis Pharma S.A.</i> , IPR2016-00627, Paper No. 1 (Petition) (P.T.A.B. Feb. 17, 2016) (“Prior Petition” or “Mylan IPR”)
2012	RESERVED
2013	RESERVED
2014	Kingston, Ch. 15, “ <i>Recent Advances in the Chemistry and Structure—Activity Relationships of Paclitaxel</i> ,” in <i>Taxane Anticancer Agents</i> , ACS Symposium Series Vol. 583, pp. 203-16 (“Kingston”)

Exhibit	Description
2015	Rowinsky <i>et al.</i> , “Taxol: the First of the Taxanes, an Important New Class of Antitumor Agents,” 19(6): 646-62, <i>Semin. Oncol.</i> , 1992 (“Rowinsky”)
2016	Stierle <i>et al.</i> , Ch. 6, “ <i>Bioactive Metabolites of the Endophytic Fungi of Pacific Yew, Taxus brevifolia,</i> ” in <i>Taxane Anticancer Agents</i> , ACS Symposium Series, Vol. 583, pp. 81-97 (Georg <i>et al.</i> , eds., 1994) (“Stierle”)
2017	RESERVED
2018	W. Mellado <i>et al.</i> , Preparation and Biological Activity of Taxol Acetates, 124 <i>BIOCHEM. BIOPHYS. RESEARCH COMM.</i> 329 (1984)
2019	U.S. Patent No. 5,352,806
2020	<i>Mylan Labs. Ltd. v. Aventis Pharma S.A.</i> , IPR2016-00627, Paper No. 10 (P.T.A.B. Aug. 23, 2016)
2021	<i>Mylan Labs. Ltd. v. Aventis Pharma S.A.</i> , IPR2016-00627, Paper No. 12 (P.T.A.B. Jan. 26, 2017)
2022	Excerpted transcript of the May 12, 2016 videotaped deposition of Dr. Hervé Bouchard, at 177:1–181:25

Exhibit	Description
2023	Excerpted transcript of the September 27, 2017 trial testimony of Dr. Hervé Bouchard, at 1004–09; 1042–58

Date: February 8, 2019

Respectfully submitted,

By: /Daniel J. Minion/  
Daniel J. Minion (Reg. No. 53,329)  
Venable LLP  
1290 Avenue of the Americas  
New York, NY 10104  
Tel: 212-218-2538  
Fax: 212-218-2200  
DMinion@Venable.com

*Attorney for Patent Owner,  
Sanofi Mature IP*

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.